试用视觉搜索
使用图片进行搜索，而不限于文本
你提供的照片可能用于改善必应图片处理服务。
隐私策略
|
使用条款
在此处拖动一张或多张图像或
浏览
在此处放置图像
或
粘贴图像或 URL
拍照
单击示例图片试一试
了解更多
要使用可视化搜索，请在浏览器中启用相机
English
全部
图片
灵感
创建
集合
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
自动播放所有 GIF
在这里更改自动播放及其他图像设置
自动播放所有 GIF
拨动开关以打开
自动播放 GIF
图片尺寸
全部
小
中
大
特大
至少... *
自定义宽度
x
自定义高度
像素
请为宽度和高度输入一个数字
颜色
全部
彩色
黑白
类型
全部
照片
插图
素描
动画 GIF
透明
版式
全部
方形
横版
竖版
人物
全部
脸部特写
半身像
日期
全部
过去 24 小时
过去一周
过去一个月
去年
授权
全部
所有创作共用
公共领域
免费分享和使用
在商业上免费分享和使用
免费修改、分享和使用
在商业上免费修改、分享和使用
详细了解
重置
安全搜索:
中等
严格
中等（默认）
关闭
筛选器
1200×675
pharmaphorum.com
Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn | pharmaphorum
1200×675
pharmaphorum.com
ASH: MSD’s ROR1 drug hits the target in first-line lymphoma | pharmaphorum
960×540
pharmaphorum.com
ASH: MSD’s ROR1 drug hits the target in first-line lymphoma | pharmaphorum
1200×675
pharmaphorum.com
FDA says yes to MSD’s 21-valent adult pneumococcal jab | pharmaphorum
960×540
pharmaphorum.com
PBC drug choices rise in US with OK for Gilead's seladelpar | pharmaphorum
1200×675
pharmaphorum.com
AbbVie gets continuous Parkinson's drug over the line in US | pharmaphorum
1200×675
pharmaphorum.com
Ipsen doubles up in TCEs for cancer, adding Biomunex drug | pharmaphorum
960×540
pharmaphorum.com
AI firm Generate signs $1bn discovery deal with Novartis | pharmaphorum
1200×675
pharmaphorum.com
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD | pharmaphorum
900×500
pharmaphorum.com
Elon Musk’s Neuralink brain interface chip set for human trials | pharmaphorum
960×540
pharmaphorum.com
FDA says yes to MSD’s 21-valent adult pneumococcal jab | pharmaphorum
1200×675
pharmaphorum.com
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD | pharmaphorum
960×540
pharmaphorum.com
In shock move, EU panel rejects Alzheimer's drug Leqembi | pharmaphorum
1200×675
pharmaphorum.com
Lundbeck planning for four novel drugs in phase 3 in 2026 | pharmaphorum
960×540
pharmaphorum.com
Pfizer’s new cancer unit sees eight new blockbusters by 2030 | pharmaphorum
1200×675
pharmaphorum.com
Biotech Showcase marking 17 years of innovation and opportunity | pharmaphorum
960×540
pharmaphorum.com
Adcendo licenses Multitude anti-TF ADC in $1bn+ deal | pharmaphorum
1200×675
pharmaphorum.com
FDA kicks off review of Cytokinetics' aficamten for HCM | pharmaphorum
960×540
pharmaphorum.com
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD | pharmaphorum
1200×675
pharmaphorum.com
Sandoz gets first FDA OK for denosumab biosimilars | pharmaphorum
1200×675
pharmaphorum.com
Galderma adds new indication for blockbuster hope Nemluvio | pharmaphorum
960×540
pharmaphorum.com
Boehringer buys oncology player Nerio in $1.3bn deal | pharmaphorum
960×540
pharmaphorum.com
Pfizer pulls sickle cell med Oxbryta off market after deaths | pharmaphorum
1200×675
pharmaphorum.com
Name change for Johnson & Johnson offshoot to Kenvue | pharmaphorum
840×473
pharmaphorum.com
Growing pains: how the pharmaceutical industry can hire and retain talent during industry boom ...
1200×675
pharmaphorum.com
Adcendo raises $135m for cancer ADCs, and other financings | pharmaphorum
1200×675
pharmaphorum.com
Bausch + Lomb dips on rumour of failing takeover talks | pharmaphorum
1200×675
pharmaphorum.com
Relief for Chinese biotechs as BIOSECURE Act delayed | pharmaphorum
1200×675
pharmaphorum.com
Generative AI in clinical trials: Practical use cases and common concerns | pharmaphorum
1200×675
pharmaphorum.com
Neuralink unveils trial linking brain implant to robotic arm | pharmaphorum
1200×675
pharmaphorum.com
Novartis raises mid-term sales outlook on pipeline promise | pharmaphorum
1200×675
pharmaphorum.com
Atlas closes $450m biotech fund, and other financing news | pharmaphorum
960×540
pharmaphorum.com
Relief for Chinese biotechs as BIOSECURE Act delayed | pharmaphorum
960×540
pharmaphorum.com
GSK’s twice-yearly asthma drug clears two phase 3 trials | pharmaphorum
900×500
pharmaphorum.com
Rebranded Servier eyes €3bn in cancer drug sales by 2030 | pharmaphorum
某些结果已被隐藏，因为你可能无法访问这些结果。
显示无法访问的结果
报告不当内容
请选择下列任一选项。
无关
低俗内容
成人
儿童性侵犯
反馈
反馈
